Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Follicular 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Prostatic Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Hepatic Impairment 1

Interventions

Cyclophosphamide 48fludarabine phosphate 36Methotrexate 26Cytarabine 24fludarabine 23Whole-Body Irradiation 23Rituximab 19Cyclosporine 19Antilymphocyte Serum 18Peripheral Blood Stem Cell Transplantation 17Filgrastim 17Busulfan 17Mycophenolic Acid 16Tacrolimus 15Azacitidine 15Alemtuzumab 15Radiotherapy 13Melphalan 13Imatinib Mesylate 13Etoposide 13Vincristine 11Methylprednisolone 11Cord Blood Stem Cell Transplantation 11Dexamethasone 10venetoclax 8Granulocyte Colony-Stimulating Factor 8Clofarabine 8thymoglobulin 7sargramostim 7nilotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia × tazemetostat × Clear all
NCT05983965 2026-04-17

Study of Tazemetostat in Lymphoid Malignancies

University of Alabama at Birmingham

Phase 1 Terminated
6 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡